Ipatasertib

Roche Abandons AKT Prostate Cancer Asset
BioSpace
Thu, 02/2/23 - 10:52 am
Roche
AKT inhibitors
Ipatasertib
clinical trials
castration-resistant prostate cancer
prostate cancer
AstraZeneca beats Roche twice in a day
EP Vantage
Wed, 10/26/22 - 10:20 am
AstraZeneca
Roche
SERD
breast cancer
Ipatasertib
capivasertib
Camizestrant
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
Fierce Biotech
Sun, 09/20/20 - 08:02 pm
Roche
prostate cancer
ESMO
JNJ
Ipatasertib
Zytiga
Roche phase 3 hits goal in subgroup of prostate cancer patients
Fierce Biotech
Fri, 06/19/20 - 11:29 am
Roche
clinical trials
Ipatasertib
prostate cancer
The ipatasertib curate’s egg
EP Vantage
Fri, 06/19/20 - 10:45 am
Roche
akt protein inhibitor
prostate cancer
Ipatasertib
Big pharma heads towards important readouts
EP Vantage
Wed, 05/20/20 - 10:22 am
Ozempic
Novo Nordisk
etrolizumab
Roche
Ipatasertib
finerenone
Bayer
filgotinib
Gilead Sciences
Galapagos
Avalglucosidase alfa
Sanofi
Rinvoq
AbbVie
clinical trials
Roche's ipatasertib-Tecentriq combo leads to 73% ORR in TNBC patients
BioCentury
Mon, 04/1/19 - 09:32 pm
Roche
clinical trials
Ipatasertib
metastatic triple-negative breast cancer
AACR
Genentech granted FDA orphan status for gastric cancer treatment
Yahoo/Fly on the Wall
Fri, 05/2/14 - 09:53 am
Genentech
FDA
gastric cancer
cancer of the gastro-esophageal junction
orphan drugs
Ipatasertib